Everest Medicines Reports Remarkable Financial Growth for 2024 Fiscal Year Everest Medicines has unveiled its financial results for the 2024 fiscal year, showcasing a major revenue increase of 461% and a successful launch of NEFECON in China.

Everest Medicines Reports Remarkable Financial Growth for 2024 Fiscal Year #China #Shanghai #Everest_Medicines #NEFECON #XERAVA